Biotechnology Opportunities in Israel

An Expert's View about Biotechnology in Israel

Posted on: 4 Oct 2010

The Israeli Biotechnology Industry is growing fast and has the potential to be one of the world leaders. Its Life Science Industry is still young, yet expanding and exuberant.

Sector briefing Biotechnology Opportunities in Israel Why Israel? The Israeli Biotechnology Industry is growing fast and has the potential to be one of the world leaders in this field. Israel enjoys a strong entrepreneurial culture which enables new ideas to be nurtured and developed. The Israeli Life Science Industry is still young, yet expanding and exuberant. Of the existing 1,000+ companies, some 80% were founded during the last decade. rd Israel is now Britain's 3 largest export market in the Middle East, and 28th largest export market world wide. The Israel business community is familiar with UK business practice, there is no language problem and there exists a free trade agreement between the EU and Israel. Furthermore there are no barriers to business and Israel's commercial ?Israel?s total number of law is rooted in English law. granted patents positions it in first place world-wide in Find general information on the Israel market patents per capita, and conditions on UKTI?s website. The Doing number four in the world in Business Guide for Israel gives an overview of the absolute number of Israel?s economy, business culture, potential patents approved.? opportunities and an introduction to other relevant issues. UK Trade & Investment Sector briefing: Biotechnology Opportunities in Israel Opportunities Teva Pharmaceuticals This is a young and fast growing industry, and One of Israel?s biggest companies which has the number of new companies being created is become one of the world?s largest relatively constant, as can be seen from the pharmaceutical companies, mainly fact that over 100 new companies have been concentrating on the manufacturing of generic established in the last 2 years. While Biotech drugs, with sales last year of $13.9 billion. companies take longer to develop marketable products than in other high tech sectors, the Recently, in order to protect its drug pipeline, rewards are bigger and last longer. Teva has entered the biotechnology sector in a major way and is actively seeking good The major sectors are: business opportunities. ? Diagnostics Companies to Watch ? Drug Discovery ? Cell & Tissue Therapy While strong on technological innovation and ? Genetics entrepreneurship, many of the smaller Israeli ? Immunology and Biomaterials. companies are sometimes weak in business acumen, management experience and The main industry drivers are: international marketing. In these areas there are good opportunities for UK companies. ? Active Technology Transfer companies Some of the leading companies are: ? Commercialised defence technologies ? Strong entrepreneurial spirit Colbar: have developed collagen implants. ? Powerful VC community ? Highly skilled workforce Cure Tech: develops novel broad spectrum ? A high per capita expenditure on R & D immune modulating products for cancer. ? Government and institutional incentives. Kamada: a biopharmaceutical company that Sales in the Life Science sector in 2009 were in develops and produces life-saving therapeutics excess of $6 billion as compared to only $390 using chromatographic purification technology. million in 1998. Smart Biotech: stimulates antibody Technological Incubators production for quick HIV / HCV testing. Israel boasts a network of 24 Technological Government Support Incubators situated throughout the country. They were established with the help of There is a wide range of Government financial Government funding in the early 1990?s but support for the biotech industry which is mainly have all now been privatised and are managed provided through the Office of the Chief by private sector companies. Some examples Scientist in the Ministry of Industry Trade and of successful graduate companies are: Labour. Biotechnology has been declared a ?preferred sector? with increased efforts for Compugen: a genomics based drug and cooperation between academia and industry, diagnostic discovery company. and additional funding to ensure the successful transition from start-up stage to a profitable D Pharm: designs and develops platform enterprise. Some examples of this are: technologies for brain disorders. Pronto Diagnostics: are developing tools for Enzymotec: produces and develops innovative the diagnosis of rare fevers. biofunctional ingredients for the entire life cycle. Omrix: have developed biological glue for immunotherapy. Protalix: Plant cell based recombinant protein expression technology. Cell Cure: have developed new therapies for neurological diseases. BioLineRx: design and production of a schizophrenia drug. UK Trade & Investment Sector briefing: Biotechnology Opportunities in Israel Stem Cells It is now impossible to refer to the If you have any questions on the opportunities biotechnology sector without including Stem above, please get in touch with the UKTI Cell companies. Israel is an acknowledged contacts named in this report. Business world leader in stem cell research and its opportunities aimed specifically at UK commercialisation, and Israeli scientists have companies are added daily to UKTI?s website. published more stem cell research articles than These leads are sourced by our staff overseas any other country on a per capita basis. in British Embassies, High Commissions and Consulates, across all sectors and in over 100 The Consortium Bereshit for Cell Therapy markets. (Bereshit is the Hebrew word for the Book of Genesis ? The Beginning), brings together both You can be alerted to business opportunities on academia and industry to further develop stem a regular basis by registering on the UKTI cell-based therapies. It comprises all of the website. More on UKTI?s business opportunities major universities and hospitals. Among the service leading companies in this niche sector are: Brainstorm Cell Therapeutics: is developing solutions for terminal neuro-degenerative diseases which also include Parkinson's Disease and Multiple Sclerosis. Gamida-Cell: looking to generate sufficient stem cells for treatment of cancer and auto- immune diseases, as well as for future regenerative cell-based medicines. M.G.V. Systems: is developing novel therapeutic modalities for cardiovascular medicine based on gene and cell therapy to help prevent graft failure. Pluristem Life Systems Inc: is developing a technology for the treatment of adult patients who require bone marrow transplants but are unable to find suitable donors. Tissera Inc: is working on tissue transplantation therapies based on an approach employing organ-specific precursor tissues. And Finally There are many promising business prospects for UK company partnerships and collaborations in Israel?s flourishing biotechnology market. Its technological innovation, strong scientific personnel, good co-operation between academia and industry and unquenchable entrepreneurial spirit, make Israel an important and worthwhile market for UK companies. Israel is an exciting and valuable market with many realistic opportunities for good business. UK Trade & Investment Sector briefing: Biotechnology Opportunities in Israel Major events and activities UKTI contacts "BioMed Israel" the Israel Life Science and Yigal Levine Technology Week Exhibition and Conference Senior Trade & Investment Advisor is due to take place at the David 192 Hayarkon Street Intercontinental Hotel & Convention Centre in Tel Aviv 63405 Tel Aviv. Tel: +972 3 7251238 Fax: +972 3 5143313 Contact: Yigal Levine E-m: yigal.levine@fco.gov.uk For details: www.kenes.com/biomed th th Time: June 14 ? 16 2010 http://ukinisrael.fco.gov.uk www.ukti.gov.uk The bi-annual Analiza Exhibition for Laboratory Technologies, Biotechnology Margaret Henderson and Chemical Ananlysis is due to take place Senior Trade & Investment Assistant at the David Intercontinental Hotel & 192 Hayarkon Street Convention Centre in Tel Aviv. Tel Aviv 63405 Tel: +972 3 7251232 Contact: Yigal Levine Fax: +972 3 5143313 For details: www.stier.co.il/english E-m: margaret.henderson@fco.gov.uk th th Time: April 26 ? 27 2010 http://ukinisrael.fco.gov.uk www.ukti.gov.uk Find full details of all events in this country and sector on the UKTI website. New export events are added daily to the site and you can register to be alerted to them on a daily, weekly or monthly basis UKTI?s Tradeshow Access Programme (TAP) provides grant support for eligible Small & Medium Sized Enterprises (SME's) to attend trade shows overseas. Find out more about UKTI support for attendance at overseas events. UK Trade & Investment Sector briefing: Biotechnology Opportunities in Israel Next steps - How UKTI can help ? Arranging appointments British companies wishing to develop their ? Organise seminars or other events for business in the Israel market are advised to you to meet contacts and promote your undertake as much market research and company in the Israeli market planning as possible in the UK. UKTI?s team in Israel, with its wide local knowledge and This work is available via our Overseas Market experience, can provide a range of services to Introduction Service (OMIS) a chargeable British-based companies wishing to grow their service which assists British-based companies business in global markets. wishing to enter or expand their business in overseas markets. This can include: ? Provision of market information To find out more about commissioning this ? Validated lists of agents/distributors work, or accessing other UKTI services and ? Key market players or potential specialist advice, please visit the UKTI website customers in the Israeli market to find contact details for your local UKTI ? Establishment of interest of such office. contacts in working with you. Whereas every effort has been made to ensure that the information given in this document is accurate, neither UK Trade & Investment nor its parent Departments (the Department for Business, Innovation & Skills, and the Foreign & Commonwealth Office), accept liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted as to the standing of any individual, firm, company or other organisation mentioned. Published 2010 by UK Trade & Investment. Crown Copyright © UK Trade & Investment Sector briefing: Biotechnology Opportunities in Israel
Posted: 04 October 2010